UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treat-to-target trials: uses, interpretation and review of concepts

Diabetes, obesity & metabolism, 2014-03, Vol.16 (3), p.193-205

Garber, A. J.

2014

Volltextzugriff (PDF)

Obesity and type 2 diabetes: which patients are at risk?

Diabetes, obesity & metabolism, 2012-05, Vol.14 (5), p.399-408

Garber, A. J.

2012

Volltextzugriff (PDF)

Will the next generation of basal insulins offer clinical advantages?

Diabetes, obesity & metabolism, 2014-06, Vol.16 (6), p.483-491

Garber, A. J.

2014

Volltextzugriff (PDF)

Risk Factors for Adverse Drug Events Among Older Adults in the Ambulatory Setting

Journal of the American Geriatrics Society (JAGS), 2004-08, Vol.52 (8), p.1349-1354

2004

Volltextzugriff (PDF)

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2011-04, Vol.13 (4), p.348-356

2011

Volltextzugriff (PDF)

The primate extinction crisis in China: immediate challenges and a way forward

Biodiversity and conservation, 2018-11, Vol.27 (13), p.3301-3327

2018

Volltextzugriff (PDF)

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Diabetes, obesity & metabolism, 2009-12, Vol.11 (12), p.1163-1172

2009

Volltextzugriff (PDF)

Methods to enhance delivery of prandial insulin and basal-prandial insulin

Diabetes, obesity & metabolism, 2013-03, Vol.15 (s1), p.11-17

Garber, A. J.

2013

Volltextzugriff (PDF)

Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)

Diabetes, obesity & metabolism, 2006-01, Vol.8 (1), p.58-66

2006

Volltextzugriff (PDF)

Advocacy and Activism as Essential Tools in Primate Conservation

International journal of primatology, 2022-02, Vol.43 (1), p.168-184

Garber, Paul A.

2022

Volltextzugriff (PDF)

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study

Diabetes, obesity & metabolism, 2007-03, Vol.9 (2), p.166-174

2007

Volltextzugriff (PDF)

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

International journal of clinical practice (Esher), 2011-04, Vol.65 (4), p.397-407

2011

Volltextzugriff (PDF)

Liraglutide in oral antidiabetic drug combination therapy

Diabetes, obesity & metabolism, 2012-04, Vol.14 (s2), p.13-19

Garber, A. J.

2012

Volltextzugriff (PDF)

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

Diabetes, obesity & metabolism, 2008-11, Vol.10 (11), p.1047-1056

2008

Volltextzugriff (PDF)

Vertical Distance from the Crest of Bone to the Height of the Interproximal Papilla Between Adjacent Implants

Journal of periodontology (1970), 2003-12, Vol.74 (12), p.1785-1788

2003

Volltextzugriff (PDF)

What is the best approach to glycaemic control in patients with type 2 diabetes?

Diabetes, obesity & metabolism, 2015-02, Vol.17 (2), p.105-106

Garber, A. J.

2015

Volltextzugriff (PDF)

Study and Modeling of Slab Deformation Processes in the Roughing Stands of Severstal’s Mill-2000 Hot-Rolling Line

Metallurgist (New York), 2021-09, Vol.65 (5-6), p.564-570

2021

Volltextzugriff (PDF)

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

Diabetes, obesity & metabolism, 2013-08, Vol.15 (8), p.760-766

2013

Volltextzugriff (PDF)

Principal Drivers and Conservation Solutions to the Impending Primate Extinction Crisis: Introduction to the Special Issue

International journal of primatology, 2022-02, Vol.43 (1), p.1-14

2022

Volltextzugriff (PDF)

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

Annals of internal medicine, 1999-05, Vol.130 (10), p.800

1999

Volltextzugriff (PDF)

Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide

Diabetes, obesity & metabolism, 2012-04, Vol.14 (s2), p.41-49

2012

Volltextzugriff (PDF)

Palladium-catalysed electrophilic aromatic C–H fluorination

Nature (London), 2018-02, Vol.554 (7693), p.511-514

2018

Volltextzugriff (PDF)

Current challenges in type 2 diabetes

Diabetes, obesity & metabolism, 2012-04, Vol.14 (s2), p.1-3

Garber, A. J.

2012

Volltextzugriff (PDF)

Response to Pokharna and Kanna: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes

Diabetes, obesity & metabolism, 2008-05, Vol.10 (5), p.436-437

Garber, A.

2008

Volltextzugriff (PDF)

1 – 25 von 3.051

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.878)
Mit Volltextzugriff
(2.440)

Publikationsform

Sprache

Englisch
(3.050)
Japanisch
(3)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Treat-to-target trials: uses, interpretation and review of concepts

Obesity and type 2 diabetes: which patients are at risk?

Will the next generation of basal insulins offer clinical advantages?

Risk Factors for Adverse Drug Events Among Older Adults in the Ambulatory Setting

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

The primate extinction crisis in China: immediate challenges and a way forward

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Methods to enhance delivery of prandial insulin and basal-prandial insulin

Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)

Advocacy and Activism as Essential Tools in Primate Conservation

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

Liraglutide in oral antidiabetic drug combination therapy

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

Vertical Distance from the Crest of Bone to the Height of the Interproximal Papilla Between Adjacent Implants

What is the best approach to glycaemic control in patients with type 2 diabetes?

Study and Modeling of Slab Deformation Processes in the Roughing Stands of Severstal’s Mill-2000 Hot-Rolling Line

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

Principal Drivers and Conservation Solutions to the Impending Primate Extinction Crisis: Introduction to the Special Issue

Impending extinction crisis of the world's primates: Why primates matter

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide

Palladium-catalysed electrophilic aromatic C–H fluorination

Current challenges in type 2 diabetes

Response to Pokharna and Kanna: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes

Aktive Filter

Suchergebnisse filtern